TuttleRM, LeboeufR, ShahaA. 2008. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol, 97:712–716.
2.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
3.
CastagnaMG, BelardiniV, CipriC, TheodouropulusA, PaciniF. 2010. The clinical impact of an “ongoing risk stratification” in patients with differentiated thyroid carcinoma. Abstract. International Thyroid Congress: Paris.
4.
TuttleRM, TalaH, ShahJ, LeboeufR, GhosseinR, GonenM, BrokhinM, OmryG, FaginJA, ShahaA. 2010. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid, 20:1341–1349.
5.
MiyauchiA, KudoT, MiyaA, KobayashiK, ItoY, Shimoyamate-doriC, TakamuraY, HigashiyamaT, FukushimaM, KiharaM, TomodaC, InoueH, YabutaT, MasuokaH. 2011. Prognostic impact of serum thyroglobulin doubling-time under TSH suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid, 21:707–716.
6.
MiyauchiA, OnishiT, MorimotoS, TakaiS, MatsuzukaF, KumaK, MaedaM, KumaharaY. 1984. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg, 199:461–466.
7.
PaciniF, AgateL, EliseiR, CapezzoneM, CeccarelliC, LippiF, MolinaroE, PincheraA. 2001. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab, 86:4092–4097.
